Adenine phosphoribosyltransferase (APRT) deficiency is a rare, inherited disorder of purine recycling (the “salvage pathway”). In healthy cells, the APRT enzyme converts adenine into adenosine monophosphate (AMP) so the body can reuse it. When APRT is missing or very low, excess adenine is instead broken down by another enzyme into a substance called 2,8-dihydroxyadenine (2,8-DHA). 2,8-DHA is extremely insoluble in urine. It forms crystals that clump together into stones inside the kidneys and urinary tract. These crystals can also clog tiny kidney tubules, causing inflammation and scarring. Without proper diagnosis and treatment, people may develop repeated kidney stones, acute kidney injury, chronic kidney disease, and even kidney failure. The condition is autosomal recessive, which means a child must inherit one faulty APRT gene from each parent. Early recognition matters because simple, effective medicines (like allopurinol or febuxostat) and lifestyle steps (good hydration and a low-purine diet) can prevent new crystal formation, protect the kidneys, and often normalize life.
APRT deficiency is a rare, inherited enzyme problem. The APRT enzyme normally recycles adenine inside cells. When the enzyme does not work, adenine is changed into a substance called 2,8-dihydroxyadenine (DHA) by xanthine oxidoreductase. DHA does not dissolve well in urine. It forms crystals and stones inside the kidneys and urinary tract. These crystals can block urine flow, cause pain, blood in urine, and infections, and slowly damage the kidney filters. Without treatment, some people develop chronic kidney disease or kidney failure. APRT deficiency is autosomal recessive: a person gets a faulty gene from both parents. Diagnosis is made by finding DHA crystals or stones, enzyme testing in cells, and/or genetic testing of the APRT gene. The most important treatment is lowering DHA production with a xanthine oxidase inhibitor (usually allopurinol; sometimes febuxostat) plus lifelong high fluid intake and a low-purine diet. With correct treatment started early, kidney damage can be prevented, and stone formation usually stops.
Other names
APRT deficiency is also called 2,8-dihydroxyadenine urolithiasis, 2,8-DHA nephrolithiasis, DHA crystalline nephropathy, adenine salvage pathway deficiency, and APRT enzyme deficiency. Some reports simply use “DHA stones” or “DHA crystalluria.” In transplant medicine, it can appear as “recurrent crystalline nephropathy due to APRT deficiency” when the underlying disorder was missed before kidney transplant and crystals injure the new kidney. Older literature may say “adenine phosphoribosyl transferase deficiency” using a space or hyphen. All these terms refer to the same problem: a genetic lack of APRT enzyme that causes excess 2,8-DHA crystals and stones, which are often misidentified as uric acid stones unless special tests are done.
Types
Genetic enzyme types. Two broad enzyme patterns are described.
Type I (near-complete deficiency): APRT activity is essentially absent in all tested cells. This is the most common form in many populations. People usually form stones early and are at high risk for crystal-related kidney injury if untreated.
Type II (residual activity): APRT activity is low but not zero. This type has been reported more often in some East Asian populations. People may still form 2,8-DHA crystals and stones, but the age of onset and severity can vary. Even “partial” activity does not reliably protect the kidneys without treatment.
Clinical presentation types.
- Infant/childhood stone disease: Babies or children present with blood in the urine, colic, or urinary blockage from stones.
- Adult recurrent stone former: Adults have repeated “uric acid-like” stones that keep returning despite usual uric-acid measures; standard x-rays may miss them.
- Crystalline nephropathy without obvious stones: People develop kidney inflammation and scarring from microscopic crystals without passing classic stones.
- Post-transplant recurrence: APRT deficiency was missed before transplant; 2,8-DHA crystals injure the new kidney, causing graft dysfunction unless the diagnosis is recognized and therapy begun.
Causes
Because APRT deficiency is a genetic disease, the primary cause is the same in all patients: biallelic (two-copy) pathogenic variants in the APRT gene leading to low or absent enzyme activity. The items below explain that root cause and the many factors that trigger or worsen crystal formation in someone who has the enzyme defect.
Biallelic APRT gene mutations. Children inherit one faulty APRT gene from each carrier parent. Without enough enzyme, adenine becomes 2,8-DHA, which crystallizes and damages the kidneys.
Autosomal recessive inheritance. Family patterns with affected siblings are common. Parents are usually healthy carriers with half the normal enzyme level.
Founder effects and small gene pools. In some regions or communities, a few shared ancestral variants make APRT deficiency more common. This increases the chance that two carriers have an affected child.
Consanguinity. Marriage between relatives raises the chance that the same APRT variant is inherited from both sides.
Physiologic growth spurts. Periods of rapid growth (infancy, adolescence) increase purine turnover. In APRT deficiency, this extra adenine load can promote more 2,8-DHA formation and stones.
Dehydration. Low fluid intake concentrates the urine. Concentrated urine allows DHA crystals to stick together more easily and form stones or block tubules.
Hot climates or heavy sweating. Heat exposure and strenuous exercise raise water loss. Without extra drinking, urine becomes concentrated and crystals grow.
High-purine diet. Large amounts of purine-rich foods (organ meats, some fish, meat broths) provide more adenine precursors, feeding DHA formation.
Excessive meat or alcohol intake. These habits can increase purine load and cause relative dehydration, both of which favor DHA crystals.
Fasting or crash dieting. Catabolism increases, purine recycling is stressed, and urine may concentrate, driving crystal growth.
Intercurrent illness with vomiting or diarrhea. Fluid loss concentrates urine and raises crystal risk.
Low urine flow states. Any cause of reduced urine volume (poor intake, diuretics without enough water) permits more crystal aggregation.
Acidic urine. While 2,8-DHA is poorly soluble at many pH levels, persistently acidic urine further reduces solubility and helps crystals form.
Slow urinary drainage or obstruction. Stasis gives crystals more time to nucleate and clump, enlarging stones.
Missed or delayed diagnosis. If APRT deficiency is mistaken for simple uric acid stones, patients do not receive the correct medicine, so crystals keep forming.
Stopping allopurinol or febuxostat. These drugs block DHA formation. Stopping them re-opens the pathway and stones quickly return.
Insufficient dosing of xanthine-oxidoreductase inhibitors. Too-low doses fail to suppress DHA production, so crystals persist.
Poor adherence to hydration advice. Not meeting daily fluid goals keeps urine concentrated and crystal-friendly.
Pregnancy-related dehydration and hyperemesis. Some people worsen during pregnancy because of vomiting and fluid loss. With prevention and medication, risk can be reduced.
Coexisting kidney disease. Reduced kidney function lowers clearance and changes urine chemistry, making it easier for crystals to accumulate.
Symptoms
Flank or side pain. Sharp or cramping pain occurs when a stone moves or blocks urine flow. Pain may come in waves and can be severe.
Blood in the urine. Urine can look pink, red, or tea-colored. Microscopic blood may be present even when color looks normal.
Frequent urination. Irritation from crystals or small stones can make you feel like you need to pass urine more often.
Burning with urination. Rough crystals scratch the urinary lining and cause stinging or burning.
Passing tiny gravel or sand. People may notice gritty particles in urine, which are small crystal clusters.
Nausea and vomiting. Severe colicky pain from a moving stone often triggers nausea.
Urgency or difficulty starting urination. Swelling and irritation can alter urine flow.
Urinary tract infections. Stones can harbor bacteria and block drainage, so infections can occur.
Fever with back pain. This suggests infection behind a blockage and needs urgent medical care.
Swelling of legs or face. When kidney function drops, the body holds extra salt and water, causing edema.
Foamy urine. Protein leakage from crystal-induced kidney damage may make urine appear foamy.
High blood pressure. Injured kidneys struggle to balance salt and hormones, leading to hypertension.
Fatigue and low appetite. Chronic kidney disease can cause tiredness, poor appetite, and weight loss.
Poor growth in children. Recurrent stones and kidney stress can affect nutrition and growth if untreated.
After kidney transplant: graft dysfunction. If APRT deficiency was unrecognized, new crystals can injure the transplanted kidney, causing rising creatinine.
Diagnostic tests
A) Physical examination (bedside observations)
Vital signs and general appearance. The clinician checks blood pressure, pulse, temperature, and hydration. Fever and high heart rate may point to infection or severe pain. High blood pressure and signs of dehydration (dry mouth, low skin turgor) can accompany stone episodes or kidney stress.
Abdominal and flank tenderness. Gentle pressing over the flanks or lower abdomen may reproduce pain where a stone is lodged. This helps localize the side and suggests obstruction.
Costovertebral angle (CVA) tenderness. Tapping over the back where the kidneys sit can cause sharp pain if the kidney is inflamed from stones or infection. This is a classic sign that the kidney itself is irritated.
Edema check and body weight. Swelling in the legs or around the eyes and changes in weight hint at salt and water retention due to reduced kidney function. Simple exam findings guide urgency and next steps.
B) Manual or bedside tests (simple point-of-care assessments)
Urine dipstick. A quick strip test at the clinic detects blood, protein, leukocyte esterase (a marker of infection), and nitrites from bacteria. It cannot identify 2,8-DHA directly, but it raises suspicion when blood is present without infection.
Urine pH measurement. A simple meter or dipstick checks urine acidity. Many patients have acidic urine, which favors crystal formation. Tracking pH helps guide diet and hydration advice.
Bedside microscopy of fresh urine. A drop of urine is examined under a microscope. 2,8-DHA crystals are typically small, brownish, and strongly birefringent under polarized light. Seeing many crystals in a patient with stones suggests APRT deficiency.
Stone strainer use at home. Patients filter urine through a fine mesh to catch passed “gravel” or stones. The specimen can then be sent for laboratory analysis to determine its chemical composition.
C) Laboratory and pathological tests (core confirmation tools)
Serum creatinine and estimated GFR. A blood test measures kidney filtering function. A rising creatinine or falling eGFR suggests crystal-related kidney injury and guides urgency of therapy.
Blood urea nitrogen and electrolytes. These show the kidney’s ability to clear waste and balance salts. Abnormal potassium or bicarbonate levels may occur in advanced disease.
Complete blood count and CRP. These are general health markers. White blood cell elevation or an increased CRP may indicate inflammation or infection around an obstructing stone.
Urinalysis with microscopy (formal lab). A full lab urinalysis confirms the presence of red blood cells, protein, and crystals. A trained technologist can describe crystal morphology and abundance more precisely than a quick bedside look.
Stone analysis by infrared spectroscopy (FTIR) or X-ray diffraction. This is the gold-standard for stone type. 2,8-DHA stones have a unique spectral pattern. Correct identification distinguishes DHA from uric acid or xanthine stones and changes treatment.
Quantitative urine 2,8-DHA assay (specialty test). Some specialized labs can measure DHA in urine using chromatography and mass spectrometry. High DHA confirms ongoing crystal production.
Erythrocyte APRT enzyme activity assay. A blood sample can measure APRT activity in red blood cells. Very low or absent activity supports the diagnosis, even between stone episodes.
Molecular genetic testing of the APRT gene. DNA testing identifies the exact variants in APRT. It confirms the diagnosis, allows family screening, and helps with genetic counseling for future pregnancies.
Urine culture. If infection is suspected, the lab grows bacteria from urine to guide antibiotic choice. Stones and obstruction increase infection risk, and timely therapy protects the kidneys.
D) Electrodiagnostic tests (limited, used for complications rather than diagnosis itself)
Electrocardiogram (ECG). APRT deficiency does not need ECG for diagnosis. However, in advanced kidney failure, potassium and other electrolytes may be abnormal and can disturb the heart’s rhythm. An ECG checks for those dangerous changes.
Nerve conduction or electromyography (rarely). These are not routine for APRT deficiency. In severe, prolonged kidney failure, some patients develop uremic neuropathy. If unexplained nerve symptoms occur, electrodiagnostic testing helps rule in or out nerve damage due to advanced kidney disease, not due to APRT itself.
E) Imaging tests (to find stones, obstruction, and kidney injury)
Renal and bladder ultrasound. Ultrasound is safe and widely available. It can show hydronephrosis (swelling due to blocked urine), stones in the kidney or ureter (sometimes hard to see if small), and bladder wall changes. It is the first-line scan for many patients, including children and pregnant people.
Non-contrast helical CT scan of the kidneys, ureters, and bladder (CT KUB). CT is very sensitive for stones and can map their size and exact location. 2,8-DHA stones are often radiolucent on plain x-ray, but CT can still detect them without contrast. CT is valuable in severe pain, fever, or unclear ultrasound results.
Plain abdominal x-ray (KUB radiograph). Many DHA stones are not visible on x-ray, so a normal film does not rule them out. Still, a KUB can help follow radio-opaque stones or serve as a quick baseline in some settings.
Doppler ultrasound for renal blood flow. In complicated cases, Doppler can assess kidney perfusion and help evaluate suspected severe obstruction or inflammation.
Transplant kidney ultrasound with Doppler (in recipients). For people who have had a kidney transplant, this test checks the graft for obstruction, swelling, or reduced blood flow when recurrent DHA crystals are suspected.
Non-pharmacological treatments
(15 physiotherapy/physical self-care + mind-body therapy + genetic/educational therapy)
1) Structured hydration plan (core strategy).
Purpose: Keep urine diluted so DHA crystals cannot aggregate.
Mechanism: Raises urine volume to ≥2–3 liters/day (adults), lowering crystal supersaturation.
Benefits: Fewer stones, less pain, kidney protection. Use a bottle with volume markings; spread intake over the day and include a glass at bedtime. For children, a clinician will set targets by weight.
2) Timed voiding and don’t “hold” urine.
Purpose: Reduce crystal dwell time in the tract.
Mechanism: Voiding every 2–3 hours clears micro-crystals.
Benefits: Less colic risk, fewer infections.
3) Gentle walking program (physiotherapy 1).
Purpose: Maintain circulation and reduce stone colic anxiety.
Mechanism: Light activity enhances gut and renal perfusion.
Benefits: Better stamina and mood; safe during stone-free periods.
4) Core stability exercises (physiotherapy 2).
Purpose: Support posture and decrease back spasm during stone episodes.
Mechanism: Strengthens deep abdominal and paraspinal muscles.
Benefits: Less musculoskeletal pain overlay.
5) Lumbar mobility stretches (physiotherapy 3).
Purpose: Relieve flank tightness.
Mechanism: Slow range-of-motion drills reduce muscle guarding.
Benefits: Comfort and easier breathing.
6) Diaphragmatic breathing (physiotherapy 4).
Purpose: Calm sympathetic overdrive in renal colic.
Mechanism: Vagal activation lowers pain perception.
Benefits: Fewer ER visits for mild episodes.
7) Heat therapy to flank (physiotherapy 5).
Purpose: Ease spasm.
Mechanism: Local vasodilation and muscle relaxation.
Benefits: Symptom relief when pain is low-to-moderate.
8) TENS (physiotherapy 6).
Purpose: Adjunct for pain modulation.
Mechanism: Gate-control of pain via cutaneous electrical stimulation.
Benefits: May reduce analgesic needs in selected patients.
9) Pelvic floor relaxation training (physiotherapy 7).
Purpose: Reduce voiding discomfort and guarding.
Mechanism: Down-training hypertonic pelvic floor.
Benefits: Smoother urination during recovery.
10) Gentle yoga (physiotherapy 8).
Purpose: Flexibility and stress reduction.
Mechanism: Slow flow with breath coordination.
Benefits: Better sleep, less anxiety.
11) Low-impact cycling or swimming (physiotherapy 9).
Purpose: Cardiovascular fitness without flank jarring.
Mechanism: Non-axial loading exercise.
Benefits: Maintains fitness during stone-free times.
12) Posture and body-mechanics coaching (physiotherapy 10).
Purpose: Reduce back strain that can mimic or worsen renal pain.
Mechanism: Ergonomic adjustments for work and home.
Benefits: Less pain confusion during monitoring.
13) Gradual activity pacing (physiotherapy 11).
Purpose: Avoid fatigue spikes that worsen pain perception.
Mechanism: Plan activity/rest intervals.
Benefits: Smoother recovery after interventions.
14) Sleep hygiene program (physiotherapy 12).
Purpose: Improve restorative sleep.
Mechanism: Fixed schedule, dark cool room, no late caffeine.
Benefits: Better pain coping and hormonal balance.
15) Flank self-massage techniques (physiotherapy 13).
Purpose: Ease myofascial tension.
Mechanism: Gentle circular motions along paraspinals.
Benefits: Comfort and relaxation.
16) Step-up hydration on hot days or exercise (physiotherapy 14).
Purpose: Prevent concentrated urine during sweating.
Mechanism: Add 500–1000 mL around workouts/heat exposure.
Benefits: Keeps specific gravity low.
17) Sick-day hydration rules (physiotherapy 15).
Purpose: Avoid dehydration with fever, vomiting, or diarrhea.
Mechanism: Oral rehydration solution; early medical help if intake falls.
Benefits: Prevents acute stone precipitation and AKI.
18) Mindfulness-based stress reduction (mind-body).
Purpose: Lower pain-related stress and catastrophizing.
Mechanism: Attention training and nonjudgmental awareness.
Benefits: Better pain control; fewer urgent visits.
19) Cognitive behavioral pain skills (mind-body).
Purpose: Reframe pain cycles and improve coping behaviors.
Mechanism: Identify triggers, practice paced breathing and cognitive reframes.
Benefits: Lower analgesic use, improved function.
20) Biofeedback for muscle relaxation (mind-body).
Purpose: Learn real-time control of tension.
Mechanism: Visual/auditory feedback of physiologic signals.
Benefits: Less guarding and urinary hesitancy.
21) Genetic counseling (genetic/educational).
Purpose: Understand inheritance, carrier testing, and family screening.
Mechanism: Review APRT variants, cascade testing, reproductive options.
Benefits: Early diagnosis in relatives; prevents kidney damage.
22) Medication literacy coaching (educational).
Purpose: Adherence to xanthine oxidase inhibitor.
Mechanism: Pill boxes, reminders, side-effect plans.
Benefits: Consistent DHA suppression; stone prevention.
23) Low-purine diet education (educational).
Purpose: Reduce adenine substrate load.
Mechanism: Limit organ meats, some fish (anchovy/sardine), and large red-meat portions; emphasize plant proteins.
Benefits: Less DHA production and uric burden.
24) Self-monitoring toolkit (educational).
Purpose: Catch problems early.
Mechanism: Symptom diary, urine color/volume tracking, “red-flag” checklist.
Benefits: Timely care, fewer complications.
25) Care coordination plan (educational).
Purpose: Keep all clinicians aligned (nephrology/urology/genetics/pediatrics).
Mechanism: Shared medication list, follow-up calendar, lab schedule.
Benefits: Safer, smoother long-term care.
Drug treatments
(Usual adult dosing shown; pediatric and renal dosing must be individualized. “Time” = how it’s taken.)
1) Allopurinol (xanthine oxidase inhibitor).
Dose/Time: Commonly 100–300 mg once daily; adjust to kidney function; some patients need higher doses under specialist care.
Purpose: First-line to stop DHA production.
Mechanism: Inhibits xanthine oxidoreductase, blocking adenine → DHA conversion.
Side effects: Rash, GI upset; rare severe hypersensitivity (risk higher with CKD or certain HLA types); liver enzyme elevation—requires monitoring.
2) Febuxostat (xanthine oxidase inhibitor).
Dose/Time: 40–80 mg once daily.
Purpose: Alternative when allopurinol not tolerated/insufficient.
Mechanism: Non-purine selective xanthine oxidase inhibitor; reduces DHA formation.
Side effects: Elevated LFTs, rash, nausea; cardiovascular safety is individualized—use specialist guidance.
3) Topiroxostat (where available). **
Dose/Time: Per local labeling (e.g., 40–80 mg/day in divided doses).
Purpose: Additional XO inhibition option in some countries.
Mechanism: XO inhibition lowers DHA.
Side effects: LFT changes, rash, GI upset. Availability varies; off-label for APRT in many regions.
4) High-volume oral fluids (medical order).
Dose/Time: Target ≥2–3 L/day; spread evenly; bedtime glass.
Purpose: Dilute urine to prevent crystal formation.
Mechanism: Lowers urinary supersaturation of DHA.
Side effects: Over-hydration risk in heart/renal failure—individualize.
5) Tamsulosin (alpha-blocker) for stone passage.
Dose/Time: 0.4 mg nightly for short courses during ureteral stone episodes.
Purpose: Facilitate passage of distal ureteral stones.
Mechanism: Relaxes ureteral smooth muscle.
Side effects: Dizziness, ejaculatory changes, orthostatic hypotension.
6) Acetaminophen (paracetamol) for pain.
Dose/Time: 500–1000 mg every 6–8 h; max 3,000 mg/day (lower in liver disease).
Purpose: First-line analgesic, kidney-safer than NSAIDs.
Mechanism: Central COX inhibition/analgesia.
Side effects: Hepatotoxicity if overdosed or combined with alcohol.
7) Short-course NSAID (e.g., ibuprofen) with caution.
Dose/Time: 200–400 mg every 6–8 h; lowest effective dose, shortest time; avoid in CKD/dehydration.
Purpose: Renal colic analgesia/anti-inflammation.
Mechanism: Peripheral COX inhibition reduces prostaglandins.
Side effects: AKI risk, GI bleeding, fluid retention—avoid if kidney function reduced.
8) Opioid rescue (e.g., tramadol) if severe pain.
Dose/Time: 50–100 mg every 6–8 h short term only.
Purpose: Breakthrough pain when other agents fail.
Mechanism: μ-receptor and SNRI effects.
Side effects: Nausea, constipation, sedation; dependence risk—use sparingly.
9) Ondansetron (antiemetic).
Dose/Time: 4–8 mg every 8–12 h as needed.
Purpose: Control nausea/vomiting during colic.
Mechanism: 5-HT3 receptor blockade.
Side effects: Headache, constipation; QT prolongation risk at high doses.
10) Antibiotics (culture-guided) for UTI.
Dose/Time: Per organism (e.g., nitrofurantoin, TMP-SMX, or others); complete full course.
Purpose: Treat infections that can worsen kidney injury.
Mechanism: Bactericidal or bacteriostatic by class.
Side effects: Class-specific; allergies, GI upset, C. difficile risk—use only when indicated.
11) ACE inhibitor (e.g., lisinopril) for proteinuria/BP.
Dose/Time: 5–20 mg once daily, titrate.
Purpose: Protect kidneys if albuminuria/hypertension.
Mechanism: RAAS blockade reduces intraglomerular pressure and fibrosis.
Side effects: Cough, hyperkalemia, creatinine rise—monitor labs.
12) ARB (e.g., losartan) if ACEI not tolerated.
Dose/Time: 25–100 mg daily.
Purpose: Kidney protection and BP control.
Mechanism: Blocks angiotensin II receptor.
Side effects: Hyperkalemia, creatinine rise—monitor.
13) Sodium bicarbonate for metabolic acidosis (selected CKD).
Dose/Time: 650 mg tablets, 1–3 tabs 2–3×/day to maintain serum bicarbonate per target.
Purpose: Correct low serum bicarbonate to slow CKD progression.
Mechanism: Alkali therapy buffers acid load (note: DHA solubility itself is not pH-responsive like uric acid).
Side effects: Bloating, sodium load—watch BP/edema.
14) Potassium citrate (selected cases).
Dose/Time: Commonly 10–30 mEq two or three times daily only if potassium and kidney function allow; discuss with clinician.
Purpose: General stone care aid; limited direct benefit for DHA stones but may help urine chemistry if mixed stone risk exists.
Mechanism: Citrate complexes calcium and can alkalinize urine; limited effect on DHA.
Side effects: GI upset; hyperkalemia risk in CKD.
15) Dapagliflozin or similar SGLT2 inhibitor (if CKD with qualifying criteria).
Dose/Time: 10 mg once daily.
Purpose: Slow CKD progression and reduce albuminuria in eligible patients (diabetic and some non-diabetic CKD cohorts).
Mechanism: Tubuloglomerular feedback restores glomerular hemodynamics; anti-inflammatory effects.
Side effects: Genital mycotic infections, volume depletion—assess eligibility.
Important: The only disease-specific medicines for APRT deficiency are xanthine oxidase inhibitors (allopurinol/febuxostat; sometimes topiroxostat) plus fluid and diet. Other drugs above are supportive for symptoms or kidney protection in the right clinical context.
Dietary molecular supplements
1) Potassium citrate powder or solution.
Dose: Typical total 20–60 mEq/day split doses if safe.
Function/Mechanism: Raises urinary citrate; may help if mixed calcium stone risk; minimal direct effect on DHA.
2) Magnesium citrate.
Dose: 200–400 mg elemental Mg/day.
Function/Mechanism: Magnesium can reduce calcium stone crystallization; helps bowel regularity if opioids used.
3) Omega-3 fatty acids (EPA/DHA).
Dose: 1–2 g/day combined EPA+DHA.
Function/Mechanism: Anti-inflammatory effects that may support CKD care and BP control.
4) Vitamin D (if deficient).
Dose: Per lab-guided repletion (e.g., 800–2000 IU/day maintenance).
Function/Mechanism: Bone-mineral support in CKD; do not exceed needs.
5) Probiotics (general GI health).
Dose: Per label (e.g., Lactobacillus/Bifidobacterium daily).
Function/Mechanism: Gut comfort during analgesic or antibiotic courses.
6) Citrate-rich natural intake (lemon/lime water).
Dose: Squeezed citrus in water daily.
Function/Mechanism: Modest urinary citrate boost; encourages hydration.
7) Coenzyme Q10 (optional).
Dose: 100–200 mg/day.
Function/Mechanism: Antioxidant; potential endothelial support in CKD care (evidence modest).
8) Folate and B-complex at RDA levels.
Dose: As per RDA.
Function/Mechanism: General nutritional adequacy; avoid megadoses.
9) Plant-based protein emphasis (not a pill, but “molecular” shift).
Dose: Replace some animal protein with legumes/soy as tolerated.
Function/Mechanism: Lowers purine load; reduces acid load.
10) Low-sodium pattern.
Dose: Aim <2 g sodium/day.
Function/Mechanism: Helps BP and edema control; supports kidney protection.
Supportive “immunity / regenerative / stem-cell” drugs
There are no approved stem-cell drugs or “immunity boosters” that treat APRT deficiency. Be cautious with unproven clinics. The items below are renal-protective or infection-preventive therapies that can support overall kidney health when clinically indicated.
1) Vaccinations (influenza, pneumococcal, hepatitis B as indicated).
Dose: Per national schedules.
Function/Mechanism: Reduce infection risk that can trigger AKI; protects vulnerable CKD patients.
2) ACE inhibitor (e.g., lisinopril).
Dose: 5–20 mg/day, titrate.
Function/Mechanism: Anti-proteinuric, anti-fibrotic renal protection.
3) ARB (e.g., losartan).
Dose: 25–100 mg/day.
Function/Mechanism: Similar kidney protection if ACEI not tolerated.
4) SGLT2 inhibitor (e.g., dapagliflozin).
Dose: 10 mg/day if eligible.
Function/Mechanism: Slows CKD decline through hemodynamic and metabolic pathways.
5) Erythropoiesis-stimulating agent (epoetin alfa) in CKD anemia.
Dose: Per hemoglobin-targeted protocol.
Function/Mechanism: Restores red-cell mass; improves oxygen delivery and energy.
6) Calcitriol/active vitamin D analogs (selected CKD-MBD).
Dose: Per lab-guided protocol.
Function/Mechanism: Controls secondary hyperparathyroidism; protects bone-mineral axis.
Surgeries / procedures
1) Ureteroscopy with laser lithotripsy.
Procedure: A thin scope enters through the urethra to the ureter/kidney; laser breaks stones; fragments are removed.
Why: First-line for many DHA stones causing obstruction or persistent pain.
2) Percutaneous nephrolithotomy (PCNL).
Procedure: Small back incision; tract into kidney; instruments remove large or complex stones.
Why: For large stone burden not suitable for ureteroscopy.
3) Temporary ureteral stent placement.
Procedure: A small tube left from kidney to bladder to keep urine flowing.
Why: Relieves obstruction, protects kidney, allows inflammation to settle before definitive stone removal.
4) Percutaneous nephrostomy tube.
Procedure: Catheter placed through the back directly into the kidney to drain urine.
Why: Emergency decompression when severe blockage or infection is present.
5) Kidney transplantation (for end-stage renal disease).
Procedure: Surgical placement of a donor kidney.
Why: Restores kidney function. Critical note: DHA can recur in the graft if xanthine oxidase inhibitor is not continued—hence lifelong medical therapy is essential.
(Extracorporeal shock-wave lithotripsy may be used selectively, but composition and visibility of DHA stones can limit effectiveness; urologists choose the approach after imaging and stone analysis.)
Prevention strategies
Take allopurinol/febuxostat exactly as prescribed—lifelong.
Drink enough water to keep urine very pale (aim ≥2–3 L/day unless your clinician sets a different target).
Spread fluids across the day and include a bedtime glass.
Low-purine eating pattern: smaller animal-protein portions; more plant proteins.
Limit organ meats, anchovies, sardines, and large red-meat servings.
Limit beer and high-fructose corn syrup drinks.
Avoid dehydration (travel, hot weather, exercise, illness).
Monitor blood pressure and follow kidney-protective plans (ACEI/ARB if prescribed).
Do scheduled labs (renal function, urinalysis, sometimes urinary microscopy) and attend specialist follow-up.
Screen family members through genetic counseling when appropriate.
When to see a doctor urgently
Severe flank pain, fever, chills, vomiting, or inability to keep fluids down.
Little or no urine, or blood in urine that is heavy or persistent.
Signs of infection: burning urination, urgency with fever.
Sudden swelling, shortness of breath, or very high blood pressure.
Rash, facial swelling, or severe malaise after starting a new medicine (possible drug reaction).
Any pregnancy with APRT deficiency (medication plans must be reviewed early).
After a kidney transplant, any sudden change in urine or pain (risk of DHA recurrence without therapy).
What to eat and what to avoid
Eat more of:
Water throughout the day (make it your main drink).
Citrus-infused water (lemon/lime) to support hydration and citrate intake.
Plant-forward meals: beans, lentils, tofu, whole grains, vegetables, fruits.
Low-fat dairy or fortified alternatives for calcium and vitamin D.
High-fiber foods to support gut and metabolic health.
Limit/avoid:
- Large portions of red meat (choose smaller portions when you do eat it).
- Organ meats (liver, kidney) and certain fish high in purines (anchovies, sardines).
- Beer and sugary drinks (especially high-fructose corn syrup).
- Very salty foods (fast food, processed snacks) that raise BP.
- Dehydrating habits (skipping fluids, excessive sauna/heat without extra water).
FAQs
1) Is APRT deficiency common?
No. It’s rare and often misdiagnosed as “ordinary” kidney stones. Genetic testing confirms it.
2) What causes the kidney damage?
DHA crystals and stones form because DHA does not dissolve in urine. Crystals block tubules and inflame kidney tissue.
3) What is the main treatment?
A xanthine oxidase inhibitor (usually allopurinol; sometimes febuxostat) plus high fluid intake and low-purine eating.
4) Will alkalinizing my urine dissolve DHA stones?
No. Unlike uric acid, DHA has poor solubility across urine pH, so XO inhibition—not alkalinization—is key.
5) How soon after starting allopurinol will stones stop?
Crystal formation often drops quickly, but full prevention needs consistent daily therapy and good hydration.
6) Can children be treated safely?
Yes. Pediatric nephrologists adjust doses by weight and monitor growth and labs.
7) Do I need treatment if I feel fine now?
Yes. Even without pain, DHA crystals can silently damage kidneys. Treatment prevents this.
8) Can kidney transplant cure APRT deficiency?
No. The enzyme defect is body-wide. DHA can recur in the transplant unless XO inhibitors are continued.
9) Are NSAIDs safe for pain?
Short courses may be used with caution in people with normal kidney function and good hydration, but they can worsen kidney injury. Acetaminophen is usually preferred.
10) What labs are monitored?
Kidney function (creatinine/eGFR), urinalysis, sometimes urinary microscopy for crystals, liver enzymes with XO inhibitors, blood counts, electrolytes.
11) Should family members get tested?
Yes. Genetic counseling can arrange enzyme or genetic tests for siblings/children.
12) What if I can’t tolerate allopurinol?
Febuxostat is an alternative; your specialist will weigh benefits and risks.
13) Do I need a special water type?
No. Volume matters most. Use safe, clean water you can drink consistently.
14) Can diet alone control the disease?
Diet helps, but medicine is usually required to fully block DHA production.
15) Will I have this condition for life?
Yes, but with the right daily treatment, most people can protect their kidneys and avoid stones.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 08, 2025.
